Bionanomachine Diagnostics and Nanonetwork Therapeutic in Brain Malignancies With Bionanodevice Interfaces
Bionanomachine Diagnostics and Nanonetwork Therapeutic in Brain Malignancies With Bionanodevice Interfaces
复制标题
利用生物纳米设备接口对脑恶性肿瘤进行生物纳米机器诊断和纳米网络治疗
DOI：
10.1109/tmbmc.2021.3083725
复制
发表时间：
2022
影响因子：
--
通讯作者：
Andreani D. Odysseos and Tadashi Nakano
中科院分区：
文献类型：
--
作者：
Abdelhamid Riadh Ben;Yamaguchi Yoshiki;楠 博・辻翔太郎・玉木香代子・和田陽介・永井宏達・伊藤斉子・佐野恭子・田原康玄・新村 健;首藤一幸;李碩，段広涛，酒井幹夫;Andreani D. Odysseos and Tadashi Nakano
分子通讯正在发展成为受生物启发的信息和通讯技术的超学科。分子通讯的下一个突破将在很大程度上取决于对以脑恶性肿瘤为代表的复杂疾病的深入理解。这将通过在交互式生物纳米机器及其综合管理以及外部控制的诊断和治疗干预的背景下描绘潜在的细胞和亚细胞过程来实现。在本文中，我们介绍了我们在外部可控分子通讯和脑恶性肿瘤领域的最新进展，旨在彻底改变我们诊断和治疗此类疾病的方式。最近有希望的数据涉及靶向细胞和外泌体介导的治疗诊断系统以及表型转换和网络形成。为了将外部可控分子通讯从理论概念转变为临床适用技术，我们确定了差距和挑战，并分享了我们的观点和想法，即基于生物纳米机器、纳米网络和生物纳米设备接口的诊断和治疗的进步如何通过有针对性的突破，为我们管理恶性疾病的方式带来范式转变。
Molecular Communication is evolving as a supra- discipline of bioinspired information and communication technologies. The next breakthroughs in molecular communication will greatly depend on the deep understanding of complex diseases, epitomized by brain malignancies. This will be achieved by delineating underlying cellular and sub-cellular processes in the context of interactive bionanomachines and their comprehensive management with diagnostic and therapeutic interventions controlled externally. In this paper, we present our recent progress in the fields of Externally Controllable Molecular Communication and brain malignancies, aiming towards drastic transformation in the way we diagnose and treat such disorders. Promising recent data involve targeting cell- and exosome-mediated theranostic systems as well as phenotypic switching and network formation. With the aim to transform Externally Controllable Molecular Communication from a theoretical concept to a clinically applicable technology, we identify gaps and challenges and share our views and thoughts on how advancements in diagnostics and therapeutics based on bionanomachine, nanonetwork and bionanodevice interfaces can bring a paradigm shift in the way we manage malignant disorders, via targeted breakthroughs.